Selected research
Market Analysis & Forecast
Global GFAP Antibody Market Analysis and Forecast 2026-2032
Market perspective
The global GFAP Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for GFAP Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for GFAP Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for GFAP Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for GFAP Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of GFAP Antibody include Merck, Synaptic Systems, Sino Biological, Santa Cruz Biotechnology, Proteintech, ProSci, Miltenyi Biotec, Hytest and GeneTex, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for GFAP Antibody, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of GFAP Antibody, also provides the revenue of main regions and countries. Of the upcoming market potential for GFAP Antibody, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the GFAP Antibody revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global GFAP Antibody market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for GFAP Antibody revenue, projected growth trends, production technology, application and end-user industry.
GFAP Antibody Segment by Company
Merck
Synaptic Systems
Sino Biological
Santa Cruz Biotechnology
Proteintech
ProSci
Miltenyi Biotec
Hytest
GeneTex
FineTest
Enzo Life Sciences
EnCor Biotechnology
Aviva Systems Biology
Atlas Antibodies
GFAP Antibody Segment by Type
Polyclonal
Monoclonal
GFAP Antibody Segment by Application
Immunohistochemistry Paraffin
Immunohistochemistry Frozen
Immunofluorescence
Western Blot
Others
GFAP Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GFAP Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GFAP Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GFAP Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of GFAP Antibody in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of GFAP Antibody company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, GFAP Antibody revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Polyclonal
- Monoclonal
Applications
- Immunohistochemistry Paraffin
- Immunohistochemistry Frozen
- Immunofluorescence
- Western Blot
- Others
Companies covered
- Merck
- Synaptic Systems
- Sino Biological
- Santa Cruz Biotechnology
- Proteintech
- ProSci
- Miltenyi Biotec
- Hytest
- GeneTex
- FineTest
- Enzo Life Sciences
- EnCor Biotechnology
- Aviva Systems Biology
- Atlas Antibodies
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 GFAP Antibody Market by Type
- 1.2.1 Global GFAP Antibody Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Polyclonal
- 1.2.3 Monoclonal
- 1.3 GFAP Antibody Market by Application
- 1.3.1 Global GFAP Antibody Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Immunohistochemistry Paraffin
- 1.3.3 Immunohistochemistry Frozen
- 1.3.4 Immunofluorescence
- 1.3.5 Western Blot
- 1.3.6 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 GFAP Antibody Market Dynamics
- 2.1 GFAP Antibody Industry Trends
- 2.2 GFAP Antibody Industry Drivers
- 2.3 GFAP Antibody Industry Opportunities and Challenges
- 2.4 GFAP Antibody Industry Restraints
3 Global Growth Perspective
- 3.1 Global GFAP Antibody Market Perspective (2021-2032)
- 3.2 Global GFAP Antibody Growth Trends by Region
- 3.2.1 Global GFAP Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global GFAP Antibody Market Size by Region (2021-2026)
- 3.2.3 Global GFAP Antibody Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global GFAP Antibody Revenue by Players
- 4.1.1 Global GFAP Antibody Revenue by Players (2021-2026)
- 4.1.2 Global GFAP Antibody Revenue Market Share by Players (2021-2026)
- 4.1.3 Global GFAP Antibody Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global GFAP Antibody Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global GFAP Antibody Key Players Headquarters & Area Served
- 4.4 Global GFAP Antibody Players, Product Type & Application
- 4.5 Global GFAP Antibody Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global GFAP Antibody Market CR5 and HHI
- 4.6.3 2025 GFAP Antibody Tier 1, Tier 2, and Tier 3
5 GFAP Antibody Market Size by Type
- 5.1 Global GFAP Antibody Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global GFAP Antibody Revenue by Type (2021-2032)
- 5.3 Global GFAP Antibody Revenue Market Share by Type (2021-2032)
6 GFAP Antibody Market Size by Application
- 6.1 Global GFAP Antibody Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global GFAP Antibody Revenue by Application (2021-2032)
- 6.3 Global GFAP Antibody Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Merck
- 7.1.1 Merck Company Information
- 7.1.2 Merck Business Overview
- 7.1.3 Merck GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.1.4 Merck GFAP Antibody Product Portfolio
- 7.1.5 Merck Recent Developments
- 7.2 Synaptic Systems
- 7.2.1 Synaptic Systems Company Information
- 7.2.2 Synaptic Systems Business Overview
- 7.2.3 Synaptic Systems GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.2.4 Synaptic Systems GFAP Antibody Product Portfolio
- 7.2.5 Synaptic Systems Recent Developments
- 7.3 Sino Biological
- 7.3.1 Sino Biological Company Information
- 7.3.2 Sino Biological Business Overview
- 7.3.3 Sino Biological GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.3.4 Sino Biological GFAP Antibody Product Portfolio
- 7.3.5 Sino Biological Recent Developments
- 7.4 Santa Cruz Biotechnology
- 7.4.1 Santa Cruz Biotechnology Company Information
- 7.4.2 Santa Cruz Biotechnology Business Overview
- 7.4.3 Santa Cruz Biotechnology GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.4.4 Santa Cruz Biotechnology GFAP Antibody Product Portfolio
- 7.4.5 Santa Cruz Biotechnology Recent Developments
- 7.5 Proteintech
- 7.5.1 Proteintech Company Information
- 7.5.2 Proteintech Business Overview
- 7.5.3 Proteintech GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.5.4 Proteintech GFAP Antibody Product Portfolio
- 7.5.5 Proteintech Recent Developments
- 7.6 ProSci
- 7.6.1 ProSci Company Information
- 7.6.2 ProSci Business Overview
- 7.6.3 ProSci GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.6.4 ProSci GFAP Antibody Product Portfolio
- 7.6.5 ProSci Recent Developments
- 7.7 Miltenyi Biotec
- 7.7.1 Miltenyi Biotec Company Information
- 7.7.2 Miltenyi Biotec Business Overview
- 7.7.3 Miltenyi Biotec GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.7.4 Miltenyi Biotec GFAP Antibody Product Portfolio
- 7.7.5 Miltenyi Biotec Recent Developments
- 7.8 Hytest
- 7.8.1 Hytest Company Information
- 7.8.2 Hytest Business Overview
- 7.8.3 Hytest GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.8.4 Hytest GFAP Antibody Product Portfolio
- 7.8.5 Hytest Recent Developments
- 7.9 GeneTex
- 7.9.1 GeneTex Company Information
- 7.9.2 GeneTex Business Overview
- 7.9.3 GeneTex GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.9.4 GeneTex GFAP Antibody Product Portfolio
- 7.9.5 GeneTex Recent Developments
- 7.10 FineTest
- 7.10.1 FineTest Company Information
- 7.10.2 FineTest Business Overview
- 7.10.3 FineTest GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.10.4 FineTest GFAP Antibody Product Portfolio
- 7.10.5 FineTest Recent Developments
- 7.11 Enzo Life Sciences
- 7.11.1 Enzo Life Sciences Company Information
- 7.11.2 Enzo Life Sciences Business Overview
- 7.11.3 Enzo Life Sciences GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.11.4 Enzo Life Sciences GFAP Antibody Product Portfolio
- 7.11.5 Enzo Life Sciences Recent Developments
- 7.12 EnCor Biotechnology
- 7.12.1 EnCor Biotechnology Company Information
- 7.12.2 EnCor Biotechnology Business Overview
- 7.12.3 EnCor Biotechnology GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.12.4 EnCor Biotechnology GFAP Antibody Product Portfolio
- 7.12.5 EnCor Biotechnology Recent Developments
- 7.13 Aviva Systems Biology
- 7.13.1 Aviva Systems Biology Company Information
- 7.13.2 Aviva Systems Biology Business Overview
- 7.13.3 Aviva Systems Biology GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.13.4 Aviva Systems Biology GFAP Antibody Product Portfolio
- 7.13.5 Aviva Systems Biology Recent Developments
- 7.14 Atlas Antibodies
- 7.14.1 Atlas Antibodies Company Information
- 7.14.2 Atlas Antibodies Business Overview
- 7.14.3 Atlas Antibodies GFAP Antibody Revenue and Gross Margin (2021-2026)
- 7.14.4 Atlas Antibodies GFAP Antibody Product Portfolio
- 7.14.5 Atlas Antibodies Recent Developments
8 North America
- 8.1 North America GFAP Antibody Revenue (2021-2032)
- 8.2 North America GFAP Antibody Revenue by Type (2021-2032)
- 8.2.1 North America GFAP Antibody Revenue by Type (2021-2026)
- 8.2.2 North America GFAP Antibody Revenue by Type (2027-2032)
- 8.3 North America GFAP Antibody Revenue Share by Type (2021-2032)
- 8.4 North America GFAP Antibody Revenue by Application (2021-2032)
- 8.4.1 North America GFAP Antibody Revenue by Application (2021-2026)
- 8.4.2 North America GFAP Antibody Revenue by Application (2027-2032)
- 8.5 North America GFAP Antibody Revenue Share by Application (2021-2032)
- 8.6 North America GFAP Antibody Revenue by Country
- 8.6.1 North America GFAP Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America GFAP Antibody Revenue by Country (2021-2026)
- 8.6.3 North America GFAP Antibody Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe GFAP Antibody Revenue (2021-2032)
- 9.2 Europe GFAP Antibody Revenue by Type (2021-2032)
- 9.2.1 Europe GFAP Antibody Revenue by Type (2021-2026)
- 9.2.2 Europe GFAP Antibody Revenue by Type (2027-2032)
- 9.3 Europe GFAP Antibody Revenue Share by Type (2021-2032)
- 9.4 Europe GFAP Antibody Revenue by Application (2021-2032)
- 9.4.1 Europe GFAP Antibody Revenue by Application (2021-2026)
- 9.4.2 Europe GFAP Antibody Revenue by Application (2027-2032)
- 9.5 Europe GFAP Antibody Revenue Share by Application (2021-2032)
- 9.6 Europe GFAP Antibody Revenue by Country
- 9.6.1 Europe GFAP Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe GFAP Antibody Revenue by Country (2021-2026)
- 9.6.3 Europe GFAP Antibody Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
10 China
- 10.1 China GFAP Antibody Revenue (2021-2032)
- 10.2 China GFAP Antibody Revenue by Type (2021-2032)
- 10.2.1 China GFAP Antibody Revenue by Type (2021-2026)
- 10.2.2 China GFAP Antibody Revenue by Type (2027-2032)
- 10.3 China GFAP Antibody Revenue Share by Type (2021-2032)
- 10.4 China GFAP Antibody Revenue by Application (2021-2032)
- 10.4.1 China GFAP Antibody Revenue by Application (2021-2026)
- 10.4.2 China GFAP Antibody Revenue by Application (2027-2032)
- 10.5 China GFAP Antibody Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia GFAP Antibody Revenue (2021-2032)
- 11.2 Asia GFAP Antibody Revenue by Type (2021-2032)
- 11.2.1 Asia GFAP Antibody Revenue by Type (2021-2026)
- 11.2.2 Asia GFAP Antibody Revenue by Type (2027-2032)
- 11.3 Asia GFAP Antibody Revenue Share by Type (2021-2032)
- 11.4 Asia GFAP Antibody Revenue by Application (2021-2032)
- 11.4.1 Asia GFAP Antibody Revenue by Application (2021-2026)
- 11.4.2 Asia GFAP Antibody Revenue by Application (2027-2032)
- 11.5 Asia GFAP Antibody Revenue Share by Application (2021-2032)
- 11.6 Asia GFAP Antibody Revenue by Country
- 11.6.1 Asia GFAP Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia GFAP Antibody Revenue by Country (2021-2026)
- 11.6.3 Asia GFAP Antibody Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA GFAP Antibody Revenue (2021-2032)
- 12.2 SAMEA GFAP Antibody Revenue by Type (2021-2032)
- 12.2.1 SAMEA GFAP Antibody Revenue by Type (2021-2026)
- 12.2.2 SAMEA GFAP Antibody Revenue by Type (2027-2032)
- 12.3 SAMEA GFAP Antibody Revenue Share by Type (2021-2032)
- 12.4 SAMEA GFAP Antibody Revenue by Application (2021-2032)
- 12.4.1 SAMEA GFAP Antibody Revenue by Application (2021-2026)
- 12.4.2 SAMEA GFAP Antibody Revenue by Application (2027-2032)
- 12.5 SAMEA GFAP Antibody Revenue Share by Application (2021-2032)
- 12.6 SAMEA GFAP Antibody Revenue by Country
- 12.6.1 SAMEA GFAP Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA GFAP Antibody Revenue by Country (2021-2026)
- 12.6.3 SAMEA GFAP Antibody Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst